Abstract
Background: Metabolic syndromes such as insulin resistance, type 2 diabetes and obesity share common pathogenic pathways with some age-related neurodegenerative disorders. Impaired insulin signaling, inflammation, mitochondrial dysfunction and ER stress can be both causatives and consequences in both groups of the diseases. Patients with chronic metabolic disorders therefore have potential risks to develop neurological diseases in late-age phase and vice versa those who with neurodegenerative diseases also have impairments in metabolic signaling. Method: In this review, we summarize about the interrelation between pathogenic pathways, common drug targets as well as known and developing therapeutics for these “modern” diseases. Results: There are conventional medicines for insulin resistance associated metabolic disorders such as insulin analogues, insulin sensitizers and ER stress releasers which have been suggested in the treatments of some neurodegenerative diseases. Some used or tested therapeutics such as bromocriptine, memantine and -2A adrenergic antagonists for Parkinson’s and Alzheimer’s diseases, vice versa, were promisingly shown as alternative or complementary drugs for metabolic syndromes. Conclusion: Therefore, it is important and possible to consider contemporary control and intervention for both diseases.
Keywords: Therapeutics, metabolic disorders, neurodegenerative diseases, common pathways.
Current Pharmaceutical Design
Title:Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Volume: 22 Issue: 23
Author(s): Xuan Thi-Anh Nguyen and Ly Le
Affiliation:
Keywords: Therapeutics, metabolic disorders, neurodegenerative diseases, common pathways.
Abstract: Background: Metabolic syndromes such as insulin resistance, type 2 diabetes and obesity share common pathogenic pathways with some age-related neurodegenerative disorders. Impaired insulin signaling, inflammation, mitochondrial dysfunction and ER stress can be both causatives and consequences in both groups of the diseases. Patients with chronic metabolic disorders therefore have potential risks to develop neurological diseases in late-age phase and vice versa those who with neurodegenerative diseases also have impairments in metabolic signaling. Method: In this review, we summarize about the interrelation between pathogenic pathways, common drug targets as well as known and developing therapeutics for these “modern” diseases. Results: There are conventional medicines for insulin resistance associated metabolic disorders such as insulin analogues, insulin sensitizers and ER stress releasers which have been suggested in the treatments of some neurodegenerative diseases. Some used or tested therapeutics such as bromocriptine, memantine and -2A adrenergic antagonists for Parkinson’s and Alzheimer’s diseases, vice versa, were promisingly shown as alternative or complementary drugs for metabolic syndromes. Conclusion: Therefore, it is important and possible to consider contemporary control and intervention for both diseases.
Export Options
About this article
Cite this article as:
Thi-Anh Nguyen Xuan and Le Ly, Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders, Current Pharmaceutical Design 2016; 22 (23) . https://dx.doi.org/10.2174/1381612822666160420141325
DOI https://dx.doi.org/10.2174/1381612822666160420141325 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Elucidating Neuronal and Vascular Injury Through the Cytoprotective Agent Nicotinamide
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry Glaucoma and Aging
Current Aging Science Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research Antioxidants in Treating Pathologies Involving Oxidative Damage: An Update on Medicinal Chemistry and Biological Activity of Stobadine and Related Pyridoindoles
Current Medicinal Chemistry Implications of Parkinson’s Disease Pathophysiology for the Development of Cell Replacement Strategies and Drug Discovery in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Pre-Dementia Diagnosis of Alzheimers Disease: Translating Clinicobiologic Research into Practice
Current Psychiatry Reviews In Silico Studies of (2E,5E)-2,5-bis(3-methoxy-4-hydroxy-benzylidene) Cyclopentanone on Proteins AChE and BChE Involved in Alzheimers disease and Ameliorative Effects on Paraquat Induced Oxidative Stress Markers in Drosophila melanogaster
Letters in Drug Design & Discovery Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives
Current Drug Targets In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine The Protective Effects of Jatrorrhizine on β-Amyloid (25-35)-Induced Neurotoxicity in Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Paring Down Obesity and Metabolic Disease by Targeting Inflammation and Oxidative Stress
Current Neurovascular Research Development of Effective PET and SPECT Imaging Agents for the Serotonin Transporter: Has a Twenty-Year Journey Reached its Destination?
Current Topics in Medicinal Chemistry Novel Detection System for Plant Protein Production of Pharmaceuticals and Impact on Conformational Diseases
Protein & Peptide Letters Treating Asthma as a Neuroelectrical Disorder
Inflammation & Allergy - Drug Targets (Discontinued) Oxidative Stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer’s Disease
Current Alzheimer Research